We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A group of brand and generic drugmakers has asked a federal judge to toss out a multidistrict class action lawsuit accusing them of colluding to delay generic versions of the painkiller Lidoderm, arguing that a patent infringement settlement between the parties was anything but anticompetitive. Read More
Colorado-based Allos Therapeutics and three research organizations are suing Dr. Reddy’s over its proposed generic version of the brand manufacturer’s orphan lymphoma drug Folotyn. Read More
Massachusetts-based Cubist Pharmaceuticals is suing Fresenius Kabi over its proposed generic version of Cubist’s profitable antibiotic Cubicin. Read More
Brand manufacturer Acorda is fending off at least six different generic challenges filed in the last few weeks to its multiple sclerosis drug Ampyra. Read More
A federal court has granted Mylan’s request for a temporary restraining order to halt all sales of competitor Apotex’s generic version of Paxil CR, the latest step in Mylan’s claim to generic exclusivity on GlaxoSmithKline’s blockbuster antidepressant. Read More
A group of third-party pharmaceutical payers is moving to settle part of a class action lawsuit against Pfizer-subsidiary King Pharmaceuticals and generics maker Mutual Pharmaceutical over their alleged collusion to delay a generic of the muscle relaxant Skelaxin. Read More
Brand manufacturer Mayne Pharma and Warner Chilcott, U.S. marketer of Mayne’s acne drug Doryx, have moved to settle class action claims with third party purchasers that allege the two companies inappropriately delayed generic competition on the product. Read More
Canadian pharmaceutical company Duchesnay has filed a lawsuit against generic manufacturer Actavis over its challenge to Duchesnay’s morning sickness drug Diclegis. Read More
A federal appellate judge has ordered brand firm Endo and generics manufacturer Mylan to continue negotiating a court-mandated settlement that will allow Mylan to market a generic version of Endo’s migraine drug Frova. Read More